MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

193.49
-13.33
-6.45%
After Hours: 193.49 0 0.00% 16:35 01/24 EST
OPEN
206.01
PREV CLOSE
206.82
HIGH
208.67
LOW
193.23
VOLUME
468.60K
TURNOVER
--
52 WEEK HIGH
224.02
52 WEEK LOW
70.00
MARKET CAP
5.86B
P/E (TTM)
-45.0060
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RETA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RETA News

  • Pharma and Biotech Aren’t Worried About Democratic Candidates’ Attacks Against Drugmakers
  • Barrons.com.01/17 22:40
  • Biotech Bonanza: 2020 Outlook In An Election Year
  • Seeking Alpha - Article.01/08 21:15
  • Better Buy: Geron vs. Incyte
  • MotleyFool.com.01/07 14:45
  • The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
  • Benzinga.12/24/2019 12:24

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About RETA

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
More

Webull offers Reata Pharmaceuticals Inc (RETA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.